Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Introduction and Aims.Cigarette smoking occurs frequently among individuals with methamphetamine (MA) dependence. Preclinical and clinical evidence has suggested that the common co‐abuse of MA and cigarettes represents a pharmacologically meaningful pattern. Methods.The present study is a secondary analysis of a randomised, placebo‐controlled trial of bupropion treatment for MA dependence (bupropion n = 36; placebo n = 37). A hierarchical logistic modelling approach assessed the efficacy of bupropion for reducing MA use separately among smokers and non‐smokers. Among smokers, relations between cigarettes smoked and MA use were assessed. Results.Smoking status did not affect treatment responsiveness in either the bupropion condition or the placebo condition. In the placebo condition, increased cigarette use was associated with an increased probability of MA use during the same time period. This effect was not observed in the bupropion condition. Discussion and Conclusions.Initial smoking status did not impact treatment outcomes. Among smokers, results suggest that bupropion may dissociate cigarette and MA use. The effect was modest and a precise pharmacological mechanism remains elusive. Cholinergic systems may be relevant for MA use outcomes. Future studies should continue to assess the role of smoking in MA treatment outcomes.[Brensilver M, Heinzerling KG, Swanson A‐N, Telesca D, Furst BA, Shoptaw SJ. Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment.Drug Alcohol Rev 2013;32:96–99]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bupropion is a nicotinic antagonist
Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509
Bupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234
Cited by
Heinzerling, K. G., Briones, M., Thames, A. D., Hinkin, C. H., Zhu, T., Wu, Y. N., & Shoptaw, S. J. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09883-w · Cited by 30
Self-citationStress psychobiology in the context of addiction medicine
Lemieux, A., & al'Absi, M. (2016) · Progress in Brain Research · doi:10.1016/bs.pbr.2015.08.001 · Cited by 29
Pipkin, J. A., Kaplan, G. J., Plant, C. P., Eaton, S. E., Gil, S. M., Zavala, A. R., & Crawford, C. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.06.029 · Cited by 21
“Previous human and animal studies have demonstrated that adolescent nicotine exposure is correlated with greater drug intake later in life (Brensilver et al., 2013; Russell et al., 2008).”
BackgroundInfluentialHersi, M., Corace, K., Hamel, C., Esmaeilisaraji, L., Rice, D., Dryburgh, N., Skidmore, B., Garber, G., Porath, A., Willows, M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292745 · Cited by 13
“• Aripiprazole [54], Bupropion [22, 23, 50, 80, 84, 90], Methylphenidate [66, 103], Modafinil (200 mg and 400 mg) [49, 62, 76, 96], PROMETA protocol [65], and Nacetyl cysteine [101] provided mixed results (i.”
BackgroundInfluentialMinařík, J., Gabrhelík, R., Malcolm, R., Pavlovská, A., & Miller, P. (2016) · Journal of Substance Use · doi:10.3109/14659891.2015.1045047 · Cited by 8
“…the treatment of tobacco, alcohol and opiate addiction already benefit from the use of medications, studies of medications to treat MA dependence show inconsistent and primarily negative results (Brensilver et al., 2013; Mounteney et al., 2014; Pérez-Mañá et al., 2012).”
Result
Metadata
- Authors
- BRENSILVER, M., HEINZERLING, K. G., SWANSON, A., TELESCA, D., FURST, B. A., & SHOPTAW, S. J.
- Venue
- Drug and Alcohol Review
- Publisher
- Wiley
- Published
- 2012-03-04
- Volume
- 32
- Issue
- 1
- Pages
- 96-99
- ISSN
- 0959-5236 (ISSN-L)
- 1465-3362
- OpenAlex
- W1949947453
- Cited by
- 39
- References
- 2
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.